Hanmi Pharm Licenses Obesity Drug Candidate to Genentech for $2.3 Billion

Hanmi Pharm signs a $2.3 billion licensing deal with Genentech for its obesity drug HM17321, retaining South Korean rights while Genentech handles global development.

Carried by 3 publishers across 4 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.